Hudson Therapeutics, Inc. Appoints Janice Marie McCourt as co-Chief Executive Officer and Board Member

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Hudson Therapeutics, Inc., a biotechnology company specializing in anti-inflammatory and immuno-oncology drugs, announced that Janice Marie McCourt has been appointed to co-Chief Executive Officer and a member of the Hudson Board of Directors, effective October 30, 2023.

Janice has joined Dr. Seung-Yong Seong, the current co-CEO of Hudson Therapeutics, Inc., in this new leadership role. Janice brings with her over 20 years of extensive experience in the biotechnology industry and a remarkable track record of leading several successful pharmaceutical companies.

Hudson Therapeutics, Inc., a subsidiary of Shaperon, Inc., listed on the Kosdaq of South Korea in 2022, was founded in 2023 to spearhead global clinical trials and business development of assets from Shaperon Inc., primarily focused on anti-inflammatory and immuno-oncology drugs.

Janice's responsibilities as co-CEO will encompass leading the Business Development division to foster research collaborations and licensing deals. Her unique ability to balance corporate vision with flawless planning and tactical execution will play a crucial role in achieving the company's growth objectives.

Dr. Seung-Yong Seong, co-CEO of Hudson Therapeutics, Inc. emphasized, “We have incredible opportunities as Hudson Therapeutics, Inc. enters the US market, and I'm confident that Janice, with her leadership and proven experience in the biotechnology field, will help lead to the successful growth of Hudson Therapeutics, Inc.."

Janice Marie McCourt quoted on her appointment, “Hudson’s inflammasome inhibitors pipeline of immunology clinical assets in atopic dermatitis, Covid-19, Alzheimer’s Disease, and preclinical programs focused in obesity, and other indications, combined with their nanobody platform for a variety of therapeutic areas in both oncology and inflammatory diseases stands apart from the approaches seen throughout the industry to create safer and more efficacious products without the issue of patients developing antibodies and becoming resistant to these products.” And she added, “I am excited to join Dr. Seung-Yong Seong and the exceptional executive team and look forward to contributing to Hudson becoming a leader in the immunology field, and maximizing the value for patients, physicians, and shareholders of the organization globally.”

The Board of Directors initiated a comprehensive internal and external search process to identify a co-CEO, and Janice emerged as the top candidate due to her exemplary expertise and leadership capabilities.

Ellie Jung (ellie@hudsontherapeutics.com / +1-919-384-8385)